Lotus Pharmaceutical Announces Acquisition of a Specialty Pharmaceutical Product in South Korea, Expanding Portfolio in Urology and Infectious Disease Prevention

Taipei, Taiwan, 21 May 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that it has entered into an agreement with OM Pharma, a global biopharmaceutical company headquartered in Geneva, Switzerland to acquire the assets of a specialty biopharmaceutical product for the prevention of recurrent urinary tract infections in South Korea including the transfer of marketing authorisations, trademarks, finished product inventory, and other relevant intellectual property rights.

The acquisition is expected to strengthen Lotus’ specialty portfolio and further expand its presence in South Korea, one of the Company’s key Asian markets.

The acquired product has an established clinical profile and long-standing market presence, with a differentiated positioning within its therapeutic category. It is currently marketed in more than 40 countries and reached approximately over one million patients globally in 2025. South Korea represents a key market, supported by strong physician endorsement and clinical engagement.

Petar Vazharov, Chief Executive Officer of Lotus, commented, “This acquisition in South Korea advances a deliberate strategy to further strengthen Lotus’ position in the market. It reflects our conviction to build a portfolio of differentiated brands that duly address patients’ needs.  We will continue to pursue assets across Asia that meet our high bar for value creation and public impact.”

Mr Pascal Schumacher, Chief Commercial Officer of OM Pharma commented, “This transaction supports our ongoing efforts to maintain best-in-class access to preventive solutions for patients with recurrent urinary tract infections in South Korea, while continuing to advance our innovation and R&D priorities.”

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.

OM Pharma transforms immune health with bacterial lysates-innovative therapies that train and strengthen the body’s natural defenses. By prioritizing prevention, the company helps reduce infections and protect vulnerable populations. Headquartered in Geneva, where its biotech site is also based, OM Pharma’s products are available in 100 countries and reach 16 million people globally through a trusted network of partners and affiliates. www.ompharma.com